On December 15, 2025, Humacyte, Inc. entered into a loan agreement for up to $77.5 million, including a fully funded first tranche of $40 million, to be used for working capital and repaying existing debts, with interest rates starting at 11.5%. This announcement signifies a pivotal step for Humacyte as it builds its financial strategy going forward.